A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal Cancer

NAEnrolling by invitationINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2026

Conditions

MSS/pMMR Type Metastatic Colorectal Adenocarcinoma Patients

Interventions

DRUG

Ivonescimab,TAS-102

Ivonescimab,20mg/kg,i.v.,D1,Q3w TAS-102,35mg/m2,bid,D1-5,Q2W

Trial Locations (1)

The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University#Huai'an First People's Hospital#, Huai'an

All Listed Sponsors

lead

Huai'an First People's Hospital

OTHER